Date: 2017-08-01
Type of information: Plant acquisition
Compound: pharmaceutical manufacturing facility in Bothell
Company: BMS (USA - NY) Seattle Genetics (USA - WA), a wholly owned subsidiary of Takeda Pharmaceutical (Japan)
Therapeutic area:
Type agreement: plant acquisition
Action mechanism:
Disease:
Details:
- • On August 1, 2017, Seattle Genetics announced that it has signed definitive agreements to purchase BMS' pharmaceutical manufacturing facility in Bothell, Washington. The facility, known as the Monte Villa Parkway Research Center, is a 51,000 square foot state-of-the art manufacturing and laboratory space built in 2014. Seattle Genetics plans to utilize the facility primarily for antibody production for current and future pipeline programs. As part of the transaction, the company intends to offer employment to the manufacturing facility’s current employees. The transaction is expected to close in the second half of 2017.
Financial terms:
Latest news:
Is general: Yes
